Aug 8, 2019
Il superfarmaco pagato dallo Stato (ma solo se funziona)
seen from Pakistan
seen from United States
seen from Malaysia
seen from India
seen from United States
seen from China
seen from Romania
seen from T1
seen from Germany
seen from T1
seen from Sweden
seen from Romania
seen from T1
seen from Germany
seen from United Kingdom
seen from United States
seen from T1
seen from United States
seen from Belgium
seen from T1
Il superfarmaco pagato dallo Stato (ma solo se funziona)
Currently, the focus is on developing T-cell therapies for the treatment of various types of hematological malignancies and solid tumors. #Tcell #CARTtherapies #Kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceuticals #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B26DpbPJPmB/?igshid=1w1c0fso4xo6n
Majority of the CAR-T therapies that are in the clinical development phase, including the two recently approved products, are based on second generation CARs. #Tcell #CARTtherapies #Kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceutical #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B26CXsIJDZ4/?igshid=180aljqtq37ab
Majority of the agreements inked between stakeholders in this domain were reported to be focused on research and development related to T-cell immunotherapies. #Tcell #CARTtherapies #kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceutical #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B26BrX9JZup/?igshid=1botsq4itb50w
Between 2012 and 2019, the partnership activity in the T-cell immunotherapy market has increased at a CAGR of 30+%. In fact, ~70% of deals were established post 2015, with the maximum activity being reported in 2018. #Tcell #CARTtherapies #Kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceutical #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B2yxdy8JMIn/?igshid=nh59jdb85hph
China is leading the CAR-T cell therapy field in terms of total number of active trials and supporting hospitals. This is primarily due to the fact that in China, the proportion of patients with advanced stage cancers is much higher and clinical trials are free for patients in the region. #Tcell #CARTtherapies #Kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceutical #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B2yuQ3fpOxd/?igshid=1stjbc2p7tr0t
In the last five years, there have been 18 IPOs accounting for more than USD 2.4 billion in financing of T-cell therapy-related initiatives. #Tcell #CARTtherapies #Kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceutical #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B2wp5O7JaeZ/?igshid=19dp62tcixamy
Social media is abuzz with chatter on the upcoming opportunities associated with T-cell immunotherapies. #Tcell #CARTtherapies #Kymriah #Yescarta #immunotherapy #celltherapies #biopharmaceutical #healthcare #innovative #market #research #marketsize https://www.instagram.com/p/B2wpzvIpPOH/?igshid=1xcr1qlfomxvp